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Conclusion: Rifaximin	prescribed	 for	HE	 in	patients	 listed	 for	 liver	 transplantation	
improved	outcomes	with	significant	reduction	in	admissions	related	to	spontaneous	
bacterial	peritonitis,	ascites	and	variceal	bleeding.
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1  | INTRODUC TION
The	onset	of	advanced	cirrhosis	brings	with	it	a	catalogue	of	com‐
plications	 affecting	 multiple	 organ	 systems	 and	 includes	 hepatic	
encephalopathy	 (HE),	 variceal	 bleeding,	 ascites	 and	 a	 propensity	










nosis	 of	 cirrhosis	 in	 the	 absence	 of	 any	 evidence	 of	 decompen‐



















sions	 to	 critical	 care,	 requirement	 for	prioritisation	on	 the	waiting	
list	and	mortality.
2  | MATERIAL S AND METHODS
2.1 | Study design and setting









at	 the	 time	of	 assessment.	Patients	under	 the	 age	of	18	were	ex‐
cluded	from	the	study.
2.3 | Data collection




fined	using	 the	West	Haven	criteria),14 blood ammonia concentra‐
tion	(venous),	concurrent	lactulose	therapy,	medical	co‐morbidities,	
emergency	admission	whilst	on	the	waiting	list	including	admissions	
to	 high	 dependency	 and	 intensive	 care	 beds,	 requirement	 for	 pri‐
oritisation	 (UKELD	 score	 ≥63),	 duration	 on	 the	 waiting	 list	 (days)	
and	mortality	 on	 the	waiting	 list.	 Elective	 admissions,	 such	 as	 for	
large	 volume	 paracentesis	 were	 excluded	 unless	 the	 paracentesis	
was	complicated	 (defined	as	necessitating	a	hospital	admission	for	
greater	than	24	hours)	which	may	occur	for	example	due	to	spon‐
taneous	 bacterial	 peritonitis,	 acute	 kidney	 injury	 or	 electrolyte	
disturbance.
2.4 | Statistical methods
The	 primary	 outcome	was	 defined	 as	 the	 number	 of	 days	 to	 all	
cause	 readmission	on	 the	 transplant	waiting	 list.	Secondary	out‐
comes	evaluated	included	requirement	for	prioritisation,	hospital	
admissions	with	sepsis,	variceal	bleeding,	ascites	and	hepatic	en‐
cephalopathy,	 length	 of	 hospital	 stay,	 intensive	 care	 admissions,	




CIs	 and	 non‐normally	 distributed	 data	 as	median	 and	 interquar‐
tile	 range.	Univariate	 statistical	 analysis	of	non‐normally	distrib‐
uted	unpaired	data	was	completed	using	the	Mann–Whitney	test	
and	 analysis	 of	 normally	 distributed	 data	 using	 unpaired	 t	 tests	
with	 Welch's	 correction	 assuming	 unequal	 standard	 deviations.	
Categorical	 variables	 are	 expressed	 as	 number	 and	 proportion	
and	compared	using	 the	X2	 test	or	Fisher's	exact	 test,	 as	appro‐
priate.	 Hospital	 admission	 data	 were	 presented	 as	 annualised	








sidered	 by	 subject	 knowledge	 or	 literature	 (ie	 lactulose	 use	 and	
MELD	 score)	 to	 be	 associated	with	 hospital	 readmission	 in	 end‐
stage	 chronic	 liver	 disease.	 Univariate	 and	 regression	 analyses	
were	performed	using	IBM	spss	Statistics	24	for	Mac.	A	P < 0.05 
was	considered	to	be	statistically	significant.
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3  | RESULTS
3.1 | Patient demographics
Of	 the	 622	 adult	 patients	 listed	 for	 transplantation,	 101	 were	
listed	with	HE.	Sixty‐six	patients	were	treated	with	rifaximin	and	
35	were	naïve.	There	was	a	male	preponderance	 in	both	groups	
and	 alcohol‐related	 liver	 disease	 was	 the	 most	 common	 aetiol‐
ogy.	 The	 rifaximin‐treated	 group	was	marginally	 older	mean	 age	
55	vs	49	(mean	difference	5.85	years	[95%	CI	0.72‐10.98]).	Organ	
severity	 scores	were	 similar;	mean	MELD	 score	was	 15	 (95%	CI	
14‐16)	in	the	rifaximin	cohort	and	16	(95%	CI	14‐18)	in	the	naïve	
[mean	 difference	 −1.1	 (95%	 CI	 −3.49‐1.38)].	 Mean	 Child‐Pugh	
Turcotte	 score	was	 10	 (95%	CI	 9.4‐10.2)	 in	 the	 rifaximin	 cohort	
and	10	(95%	CI	9.7‐10.9)	in	the	naïve	(mean	difference	−0.52	[95%	
CI	−1.24‐0.21]).	 82%	of	 those	on	 rifaximin	 and	71%	of	 those	on	
placebo	were	on	concurrent	 lactulose	therapy	(P	=	0.26).	Fifteen	
percent	 of	 the	 rifaximin	 cohort	 (10/66)	 were	 on	 ciprofloxacin	
prophylaxis	 (500	mg	 once	 daily)	 and	 20%	 of	 the	 rifaximin‐naive	











On	 univariate	 analysis,	 rifaximin‐treated	 patients	 had	 reduced	 all‐
cause	admissions	(elective	admissions	were	excluded)	on	the	waiting	
list	2.75	vs	6.30	 (mean	difference	−3.55	[95%	CI	−6.545	to	−0.56]	
admissions	per	 year).	Admissions	with	 episodes	of	 sepsis	 per	 year	
were	similar	between	groups	0.84	vs	1.81	 (mean	difference	−0.97	
[95%	 CI	 −2.27‐0.33]	 admissions	 per	 year).	 Admissions	 related	 to	
complications	 of	 large	 volume	 ascites	 including	 spontaneous	 bac‐
terial	 peritonitis,	 hepatorenal	 syndrome	 and	 metabolic	 disarray	

























when	adjusting	 for	 age,	 sex,	BMI,	 disease	 severity	 score	 and	 con‐
comitant	 lactulose	 use.	 Similarly,	 rifaximin	 use	was	 independently	







n = 35 P value 
Age	[mean	(95%	CI)] 55	(52‐58) 49	(45‐53) 0.007







































	NASH	cirrhosis	n	(%) 2	(3) 2	(5) ns
HCV	cirrhosis	n	(%) 11	(17) 7	(19) ns
	HBV	cirrhosis	n	(%)	 0	(0) 1	(3) ns
Autoimmune	cirrhosis	n	(%) 12	(19) 9	(24) ns
	HCC	n	(%) 7	(11) 1	(3) ns
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associated	 with	 a	 significant	 reduction	 in	 the	 number	 of	 hospital	
admissions	relating	to	variceal	bleeding,	complications	of	ascites	and	




requirement	 for	prioritisation	 (odds	 ratio	0.29	 [95%	CI	0.09‐0.93])	
when	adjusting	 for	 age,	 sex,	BMI,	 disease	 severity	 score	 and	 con‐
comitant	lactulose	use.
Of	the	31	patients	who	were	admitted	due	to	suspected	sep‐
sis,	 a	 source	 of	 infection	 was	 only	 confirmed	 in	 cultures	 in	 12	
(38.7%)	 patients	 (13/66	 [19.7%]	 on	 rifaximin	 vs	 18/35	 [51.4%]	
in	 those	 who	were	 not	 treated	 with	 rifaximin;	 P	 =	 0.016).	 This	
included	 three	episodes	of	pneumonia,	 three	episodes	of	 spon‐
taneous	bacterial	peritonitis,	 three	episodes	of	bacteremia,	 two	
cases	of	cellulitis,	one	case	of	infective	endocarditis	and	one	case	
with	 a	 breast	 abscess.	 Organisms	 cultured	 included	 vancomy‐
cin‐resistant	enterococcus,	escheria	coli,	 klebsiella	pneumoniae,	












There	 is	now	a	 robust	evidence	base	 to	 support	 rifaximin	as	a	
beneficial	 adjunctive	 therapy	 to	 lactulose	 in	 the	prevention	of	 re‐












Univariate analysis[unadjusted effect 
estimate (95% CI), P value]
Multivariate analysis 
[confounder-adjusted effect 
estimate (95% CI), P value]
All‐cause	
admissions/year
−3.55 (-6.55 – -0.55), P=0.021 −3.10 (-6.00 – -0.20), P=0.037
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score	of	≤10,	two‐thirds	with	a	MELD	score	between	11	and	18	and	











Patients	with	 advanced	 cirrhosis	 are	 susceptible	 to	 unplanned	
emergency	hospitalisations	 for	a	variety	of	 reasons,	 including	sus‐
ceptibility	 to	 infection,17	 overt	 HE,5	 acute	 kidney	 injury,	 acute	











and	infection	are	also	major	drivers	of	episodes	of	HE22,23 and have 
been	 implicated	 in	 patients	 admitted	 with	 advanced	 HE	 (grades	
3	 and	 4)	 regardless	 of	 blood	 ammonia	 levels	 and	 MELD	 score.24 






without	 ACLF.25	 It	 therefore	 follows	 that	 if	 patients	 in	 this	 study	
treated	with	rifaximin	have	reduced	all‐cause	unplanned	hospitalisa‐
tions	and	episodes	of	spontaneous	bacterial	peritonitis	that	rifaximin	




ome	which	we	 know	 exhibits	 dysbiosis	 in	 patients	with	 advanced	
cirrhosis.8,27	 Indeed,	a	 recent	systematic	 review	and	meta‐analysis	
examining	 the	 impact	 of	 rifaximin	on	 the	 development	 of	 sponta‐
neous	bacterial	peritonitis	 showed	 that	 rifaximin	may	be	effective	
in	preventing	spontaneous	bacterial	peritonitis	in	patients	with	cir‐
rhosis	 and	 ascites	 compared	 to	 systemically	 absorbed	 antibiotics	
and compared to placebo.9	Another	retrospective	study	examining	
145	patients	with	cirrhosis	showed	rifaximin	treatment	was	signifi‐
cantly	associated	with	prolonged	overall	survival	and	reduced	risks	
of	 spontaneous	 bacterial	 peritonitis,	 variceal	 bleeding	 and	 recur‐
rent	HE.28	A	further	randomised	study	of	rifaximin	vs	placebo	also	
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Our	 data	 also	 show	 that	 rifaximin	 independently	 led	 to	 a	 sig‐




the	 umbilical	 vein.	 Furthermore,	 they	 have	 small	 bowel	 bacterial	
overgrowth,	 gut	 dysbiosis	 and	 increased	 gut	 permeability	 all	 con‐
tributing	 to	 bacterial	 translocation,	 endotoxemia	 and	 systemic	 in‐
flammation.30,31	This	 pathological	 process	has	been	demonstrated	
to	 alter	 the	 hemodynamic	 circulation	 and	 could	 increase	 portal	
pressure.	Rifaximin	may	 therefore	provide	a	 therapeutic	option	 to	
prevent	portal	hypertension‐related	bleeding	by	reducing	bacterial	
translocation	 and	 endotoxin	 levels.	 However,	 a	 recent	 small	 ran‐
domised	 controlled	 trial	 reported	 that	 4	weeks	 of	 treatment	with	
rifaximin	did	not	reduce	the	hepatic	venous	pressure	gradient	or	im‐
prove	systemic	hemodynamics	in	patients	with	cirrhosis	and	ascites.	
Furthermore,	 rifaximin	 did	 not	 affect	 glomerular	 filtration	 rate	 or	
levels	of	vasoactive	hormones.32
Surprisingly,	 patients	 treated	with	 rifaximin	 did	 not	 have	 a	 re‐
duction	 in	 emergency	 encephalopathy‐related	 admissions	 per	









although	overall	 the	transplant	waiting	 list	mortality	 in	this	cohort	
was	 low	at	13.89%	so	more	patients	would	need	to	have	been	 in‐
cluded	to	detect	a	mortality	difference.	Nevertheless,	patients	who	





falls	 short,	however,	 is	 that	we	were	unable	 to	determine	 in	many	
cases	 the	 precise	 duration	 of	 rifaximin	 therapy	 prior	 to	 being	 re‐
ferred	and	listed	for	transplantation	as	many	patients	were	tertiary	












−1.40	 [95%	CI	 −3.76	 to	 0.97]	 days)	 in	 the	 naïve	 group.	Moreover,	








There	was	 a	 reduced	 requirement	 for	 prioritisation	of	 patients	on	
the	waiting	 list	 in	patients	 treated	with	rifaximin	and	an	 increased	
time	 to	hospital	 readmission.	This	 study	provides	 ‘real‐world’	data	
that	demonstrates	the	potential	value	of	rifaximin	in	reducing	hos‐
pital	 admissions	 and	 length	 of	 stay	 within	 the	 advanced	 cirrhotic	
population	awaiting	liver	transplantation.	At	this	point,	however,	the	
data	should	not	be	interpreted	as	a	reason	to	change	clinical	practice	
but	 should	act	as	a	catalyst	 for	 further	prospective	studies	 in	 this	
patient	group.
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